BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 38278659)

  • 1. Disentangling tau: One protein, many therapeutic approaches.
    Lane-Donovan C; Boxer AL
    Neurotherapeutics; 2024 Mar; 21(2):e00321. PubMed ID: 38278659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focusing on oligomeric tau as a therapeutic target in Alzheimer's disease and other tauopathies.
    Rayman JB
    Expert Opin Ther Targets; 2023; 27(4-5):269-279. PubMed ID: 37140480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tau: Clinical trials and novel therapeutic approaches.
    VandeVrede L; Boxer AL; Polydoro M
    Neurosci Lett; 2020 Jul; 731():134919. PubMed ID: 32380145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
    Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
    Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
    Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
    Cope TE; Rittman T; Borchert RJ; Jones PS; Vatansever D; Allinson K; Passamonti L; Vazquez Rodriguez P; Bevan-Jones WR; O'Brien JT; Rowe JB
    Brain; 2018 Feb; 141(2):550-567. PubMed ID: 29293892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
    Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
    Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
    Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
    Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions.
    Villemagne VL; Okamura N
    Curr Opin Neurobiol; 2016 Feb; 36():43-51. PubMed ID: 26397020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies.
    Pasinetti GM; Ksiezak-Reding H; Santa-Maria I; Wang J; Ho L
    J Neurochem; 2010 Sep; 114(6):1557-68. PubMed ID: 20569300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic landscape of tauopathies: challenges and prospects.
    Cummings JL; Gonzalez MI; Pritchard MC; May PC; Toledo-Sherman LM; Harris GA
    Alzheimers Res Ther; 2023 Oct; 15(1):168. PubMed ID: 37803386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
    Robinson JL; Lee EB; Xie SX; Rennert L; Suh E; Bredenberg C; Caswell C; Van Deerlin VM; Yan N; Yousef A; Hurtig HI; Siderowf A; Grossman M; McMillan CT; Miller B; Duda JE; Irwin DJ; Wolk D; Elman L; McCluskey L; Chen-Plotkin A; Weintraub D; Arnold SE; Brettschneider J; Lee VM; Trojanowski JQ
    Brain; 2018 Jul; 141(7):2181-2193. PubMed ID: 29878075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies.
    Panza F; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Cirillo N; Damiani C; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Lozupone M
    Expert Opin Investig Drugs; 2023; 32(7):625-634. PubMed ID: 37405389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.
    Williams DR
    Intern Med J; 2006 Oct; 36(10):652-60. PubMed ID: 16958643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
    Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
    Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy.
    Piras A; Collin L; Grüninger F; Graff C; Rönnbäck A
    Acta Neuropathol Commun; 2016 Mar; 4():22. PubMed ID: 26936765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies.
    Spina S; Brown JA; Deng J; Gardner RC; Nana AL; Hwang JL; Gaus SE; Huang EJ; Kramer JH; Rosen HJ; Kornak J; Neuhaus J; Miller BL; Grinberg LT; Boxer AL; Seeley WW
    Brain; 2019 Jul; 142(7):2068-2081. PubMed ID: 31081015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.